imfinzi
astrazeneca ab - durvalumab - karcinóma, nem kissejtes tüdő - daganatellenes szerek - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - a vakcinák - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
teriparatid teva 20 mikrogramm/80 mikroliter oldatos injekció előretöltött tollban
teva gyógyszergyár zrt. - a teriparatid -
teicoplanin aptapharma 200 mg por és oldószer oldatos injekcióhoz/infúzióhoz
apta medica internacional d.o.o. - teicoplanin -
teicoplanin aptapharma 400 mg por és oldószer oldatos injekcióhoz/infúzióhoz
apta medica internacional d.o.o. - teicoplanin -
eptifibatide mylan 2 mg/ml oldatos injekció
mylan s.a.s. - eptifibatidet -
fludarabin accord 25 mg/ml koncentrátum oldatos injekcióhoz vagy infúzióhoz
accord healthcare polska sp. z o.o. - fludarabine foszfát -
epirubicin-teva 2 mg/ml oldatos injekció vagy infúzió
teva gyógyszergyár zrt. - epirubicin -
cyclolux 0,5 mmol/ml oldatos injekció, egyadagos
sanochemia pharmazeutika gmbh - gadoteric sav -
dotagraf 0,5 mmol/ml oldatos injekció, egyadagos
bayer ag - gadoteric sav -